Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (M. S. Kovacevic) .

21 - 30 / 34
Na začetekNa prejšnjo stran1234Na naslednjo stranNa konec
21.
22.
Rak jajčnikov : česa še ne vemo? : ginekološki simpozij : Ljubljana, 2. 12. 2021 : zbornik znanstvenih prispevkov
2021, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci

Povzetek: Ginekološki simpozij Rak Jajčnika: Česa še ne vemo? zajema sklop predavanj, kjer so predstavljeni začetna obravnava žensk s tumorji v področju jajčnikov, nadaljnja predoperativna priprava, najradikalnejši kirurški posegi in zadnje smernice na področju sistemske terapije. Prav tako pozornost namenjamo tudi stereotaktičnemu obsevanju in imunoterapiji, ki na področju ginekoloških rakov počasi dobiva svojo veljavo in mesto.
Ključne besede: napredovali rak, mejno maligni tumorji, ekstraabdominalna kirurgija, citoredukcija, bevacizumab, polimorbidnost, stereotaktično obsevanje, imunoterapija, zborniki, elektronske knjige
Objavljeno v DiRROS: 10.03.2022; Ogledov: 905; Prenosov: 442
.pdf Celotno besedilo (1,31 MB)
Gradivo ima več datotek! Več...

23.
Immunotherapy for metastatic non-small cell lung cancer : real-world data from an academic Central and Eastern European center
Marija Ivanović, Lea Knez, Ana Herzog, Mile Kovačević, Tanja Čufer, 2021, izvirni znanstveni članek

Povzetek: Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Ključne besede: non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Central Europe, Europe, Eastern Europe
Objavljeno v DiRROS: 12.10.2021; Ogledov: 1159; Prenosov: 364
URL Povezava na datoteko

24.
Sledenje po zdravljenju raka jajčnikov
Nina Kovačević, 2021, objavljeni povzetek znanstvenega prispevka na konferenci

Ključne besede: rak jajčnikov, sistemsko zdravljenje, sledenje
Objavljeno v DiRROS: 16.06.2021; Ogledov: 1090; Prenosov: 549
.pdf Celotno besedilo (7,22 MB)
Gradivo ima več datotek! Več...

25.
26.
27.
28.
Priporočila za obravnavo bolnic z rakom zunanjega spolovila
Sebastjan Merlo, 2020, strokovna monografija

Objavljeno v DiRROS: 26.10.2020; Ogledov: 1562; Prenosov: 396
.pdf Celotno besedilo (874,98 KB)

29.
30.
Iskanje izvedeno v 1.67 sek.
Na vrh